Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Diagnostic amniocentesis

Alessandro Ghidini, MD
Section Editors
Louise Wilkins-Haug, MD, PhD
Deborah Levine, MD
Deputy Editor
Vanessa A Barss, MD, FACOG


Amniocentesis is a technique for withdrawing amniotic fluid from the uterine cavity using a needle via a transabdominal approach. Laboratory tests to evaluate fetal health can be performed on amniotic fluid since this fluid is largely composed of fetal substances: urine, secretions, exfoliated cells, and transudate.


The most common diagnostic indications for obtaining amniotic fluid are prenatal genetic studies and assessment of fetal lung maturity. Other indications include, but are not limited to, evaluation of the fetus for infection, degree of hemolytic anemia, blood or platelet type, hemoglobinopathy, and neural tube defects.

Amniocentesis is also performed as a therapeutic procedure to remove excess amniotic fluid, such as in symptomatic polyhydramnios or twin-twin transfusion syndrome, or to reduce volume and pressure of amniotic fluid in cases of prolapsed fetal membranes in the second trimester to facilitate placement of an emergency cerclage [1]. This procedure is termed amnioreduction and is discussed separately. (See "Twin-twin transfusion syndrome: Management and outcome", section on 'Amnioreduction' and "Polyhydramnios", section on 'Amnioreduction' and "Transvaginal cervical cerclage", section on 'Replacement of prolapsed membranes'.)


Amniocentesis, like other potentially morbid procedures, should be preceded by appropriate counseling regarding the:

Purpose of the procedure


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 8, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Locatelli A, Vergani P, Bellini P, et al. Amnioreduction in emergency cerclage with prolapsed membranes: comparison of two methods for reducing the membranes. Am J Perinatol 1999; 16:73.
  2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007; 110:1459.
  3. Gosden CM. Amniotic fluid cell types and culture. Br Med Bull 1983; 39:348.
  4. Lawin O'Brien A, Dall'Asta A, Tapon D, et al. Gestation related karyotype, QF-PCR and CGH-array failure rates in diagnostic amniocentesis. Prenat Diagn 2016; 36:708.
  5. www.acmg.net//AM/Template.cfm?Section=Home3. (Accessed October 28, 2008).
  6. Giorlandino C, Cignini P, Cini M, et al. Antibiotic prophylaxis before second-trimester genetic amniocentesis (APGA): a single-centre open randomised controlled trial. Prenat Diagn 2009; 29:606.
  7. Gramellini D, Fieni S, Casilla G, et al. Mid-trimester amniocentesis and antibiotic prophylaxis. Prenat Diagn 2007; 27:956.
  8. Tabor A, Philip J, Madsen M, et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1:1287.
  9. Kappel B, Nielsen J, Brogaard Hansen K, et al. Spontaneous abortion following mid-trimester amniocentesis. Clinical significance of placental perforation and blood-stained amniotic fluid. Br J Obstet Gynaecol 1987; 94:50.
  10. Bombard AT, Powers JF, Carter S, et al. Procedure-related fetal losses in transplacental versus nontransplacental genetic amniocentesis. Am J Obstet Gynecol 1995; 172:868.
  11. Andreasen E, Kristoffersen K. Incidence of spontaneous abortion after amniocentesis: influence of placental localization and past obstetric and gynecologic history. Am J Perinatol 1989; 6:268.
  12. Reid KP, Gurrin LC, Dickinson JE, et al. Pregnancy loss rates following second trimester genetic amniocentesis. Aust N Z J Obstet Gynaecol 1999; 39:281.
  13. Kalogiannidis I, Prapa S, Dagklis T, et al. Amniocentesis-related adverse outcomes according to placental location and risk factors for fetal loss after midtrimester amniocentesis. Clin Exp Obstet Gynecol 2011; 38:239.
  14. Crane JP, Kopta MM. Genetic amniocentesis: impact of placental position upon the risk of pregnancy loss. Am J Obstet Gynecol 1984; 150:813.
  15. Giorlandino C, Mobili L, Bilancioni E, et al. Transplacental amniocentesis: is it really a higher-risk procedure? Prenat Diagn 1994; 14:803.
  16. Kong CW, Leung TN, Leung TY, et al. Risk factors for procedure-related fetal losses after mid-trimester genetic amniocentesis. Prenat Diagn 2006; 26:925.
  17. Marthin T, Liedgren S, Hammar M. Transplacental needle passage and other risk-factors associated with second trimester amniocentesis. Acta Obstet Gynecol Scand 1997; 76:728.
  18. Pitukkijronnakorn S, Promsonthi P, Panburana P, et al. Fetal loss associated with second trimester amniocentesis. Arch Gynecol Obstet 2011; 284:793.
  19. Corrado F, Cannata ML, La Galia T, et al. Pregnancy outcome following mid-trimester amniocentesis. J Obstet Gynaecol 2012; 32:117.
  20. Harris A, Monga M, Wicklund CA, et al. Clinical correlates of pain with amniocentesis. Am J Obstet Gynecol 2004; 191:542.
  21. Van Schoubroeck D, Verhaeghe J. Does local anesthesia at mid-trimester amniocentesis decrease pain experience? A randomized trial in 220 patients. Ultrasound Obstet Gynecol 2000; 16:536.
  22. Gordon MC, Ventura-Braswell A, Higby K, Ward JA. Does local anesthesia decrease pain perception in women undergoing amniocentesis? Am J Obstet Gynecol 2007; 196:55.e1.
  23. Mujezinovic F, Alfirevic Z. Analgesia for amniocentesis or chorionic villus sampling. Cochrane Database Syst Rev 2011; :CD008580.
  24. Athanasiadis AP, Pantazis K, Goulis DG, et al. Comparison between 20G and 22G needle for second trimester amniocentesis in terms of technical aspects and short-term complications. Prenat Diagn 2009; 29:761.
  25. Seeds JW. Diagnostic mid trimester amniocentesis: how safe? Am J Obstet Gynecol 2004; 191:607.
  26. Antsaklis A, Papantoniou N, Xygakis A, et al. Genetic amniocentesis in women 20-34 years old: associated risks. Prenat Diagn 2000; 20:247.
  27. Calda P, Brestak M. Amniovacucentesis vs standard syringe technique for amniocentesis: experience with 1219 cases. Am J Obstet Gynecol 2009; 201:593.e1.
  28. American College of Obstetricians and Gynecologists. Prevention of D isoimmunization. ACOG Practice Bulletin #4, American College of Obstetricians and Gynecologists, Washington, DC 1999.
  29. Hankins GD, Rowe J, Quirk JG Jr, et al. Significance of brown and/or green amniotic fluid at the time of second trimester genetic amniocentesis. Obstet Gynecol 1984; 64:353.
  30. Zorn EM, Hanson FW, Greve LC, et al. Analysis of the significance of discolored amniotic fluid detected at midtrimester amniocentesis. Am J Obstet Gynecol 1986; 154:1234.
  31. Hess LW, Anderson RL, Golbus MS. Significance of opaque discolored amniotic fluid at second-trimester amniocentesis. Obstet Gynecol 1986; 67:44.
  32. Odibo AO, Gray DL, Dicke JM, et al. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol 2008; 111:589.
  33. Midtrimester amniocentesis for prenatal diagnosis. Safety and accuracy. JAMA 1976; 236:1471.
  34. Isada NB, Koppitch FC 3rd, Johnson MP, Evans MI. Does the color of amniotic fluid still matter? Fetal Diagn Ther 1990; 5:165.
  35. Golbus MS, Loughman WD, Epstein CJ, et al. Prenatal genetic diagnosis in 3000 amniocenteses. N Engl J Med 1979; 300:157.
  36. Cassell GH, Davis RO, Waites KB, et al. Isolation of Mycoplasma hominis and Ureaplasma urealyticum from amniotic fluid at 16-20 weeks of gestation: potential effect on outcome of pregnancy. Sex Transm Dis 1983; 10:294.
  37. Gray DJ, Robinson HB, Malone J, Thomson RB Jr. Adverse outcome in pregnancy following amniotic fluid isolation of Ureaplasma urealyticum. Prenat Diagn 1992; 12:111.
  38. Perni SC, Vardhana S, Korneeva I, et al. Mycoplasma hominis and Ureaplasma urealyticum in midtrimester amniotic fluid: association with amniotic fluid cytokine levels and pregnancy outcome. Am J Obstet Gynecol 2004; 191:1382.
  39. Nguyen DP, Gerber S, Hohlfeld P, et al. Mycoplasma hominis in mid-trimester amniotic fluid: relation to pregnancy outcome. J Perinat Med 2004; 32:323.
  40. Berg TG, Philpot KL, Welsh MS, et al. Ureaplasma/Mycoplasma-infected amniotic fluid: pregnancy outcome in treated and nontreated patients. J Perinatol 1999; 19:275.
  41. Horowitz S, Mazor M, Romero R, et al. Infection of the amniotic cavity with Ureaplasma urealyticum in the midtrimester of pregnancy. J Reprod Med 1995; 40:375.
  42. Sant-Cassia LJ, MacPherson MB, Tyack AJ. Midtrimester amniocentesis: is it safe? A single centre controlled prospective study of 517 consecutive amniocenteses. Br J Obstet Gynaecol 1984; 91:736.
  43. Tongsong T, Wanapirak C, Sirivatanapa P, et al. Amniocentesis-related fetal loss: a cohort study. Obstet Gynecol 1998; 92:64.
  44. Farahani G, Goldman MA, Davis JG, et al. Use of the ultrasound aspiration transducer in midtrimester amniocentesis. J Reprod Med 1984; 29:227.
  45. Mujezinovic F, Alfirevic Z. Technique modifications for reducing the risks from amniocentesis or chorionic villus sampling. Cochrane Database Syst Rev 2012; :CD008678.
  46. Gold RB, Goyert GL, Schwartz DB, et al. Conservative management of second-trimester post-amniocentesis fluid leakage. Obstet Gynecol 1989; 74:745.
  47. Borgida AF, Mills AA, Feldman DM, et al. Outcome of pregnancies complicated by ruptured membranes after genetic amniocentesis. Am J Obstet Gynecol 2000; 183:937.
  48. Devlieger R, Millar LK, Bryant-Greenwood G, et al. Fetal membrane healing after spontaneous and iatrogenic membrane rupture: a review of current evidence. Am J Obstet Gynecol 2006; 195:1512.
  49. Simpson JL, Socol ML, Aladjem S, Elias S. Normal fetal growth despite persistent amniotic fluid leakage after genetic amniocentesis. Prenat Diagn 1981; 1:277.
  50. Crane JP, Rohland BM. Clinical significance of persistent amniotic fluid leakage after genetic amniocentesis. Prenat Diagn 1986; 6:25.
  51. Levine D, Callen PW, Pender SG, et al. Chorioamniotic separation after second-trimester genetic amniocentesis: importance and frequency. Radiology 1998; 209:175.
  52. Isenberg SJ, Heckenlively JR. Traumatized eye with retinal damage from amniocentesis. J Pediatr Ophthalmol Strabismus 1985; 22:65.
  53. Admoni MM, BenEzra D. Ocular trauma following amniocentesis as the cause of leukocoria. J Pediatr Ophthalmol Strabismus 1988; 25:196.
  54. Cederholm M, Haglund B, Axelsson O. Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG 2005; 112:394.
  55. Vedantam R, Douglas DL. Congenital dislocation of the knee as a consequence of persistent amniotic fluid leakage. Br J Clin Pract 1994; 48:342.
  56. Eiben B, Hammans W, Goebel R, Epplen JT. Safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998; 351:1435; author reply 1435.
  57. Hislop A, Fairweather DV. Amniocentesis and lung growth: an animal experiment with clinical implications. Lancet 1982; 2:1271.
  58. Baird PA, Yee IM, Sadovnick AD. Population-based study of long-term outcomes after amniocentesis. Lancet 1994; 344:1134.
  59. Giorlandino C, Bilancioni E, D'Alessio P, Muzii L. Risk of iatrogenic fetal infection at prenatal diagnosis. Lancet 1994; 343:922.
  60. Minola E, Maccabruni A, Pacati I, Martinetti M. Amniocentesis as a possible risk factor for mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 33:1341.
  61. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 1996; 175:661.
  62. Cohen, J, Dussaix E, Bernard O. Transmission du virus de l'hepatite C de la mere a l'enfant: une etude de 44 enfants. Gastroenterol Clin Biol 1998; 22:179.
  63. Mandelbrot L, Jasseron C, Ekoukou D, et al. Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort. Am J Obstet Gynecol 2009; 200:160.e1.
  64. Floridia M, Masuelli G, Meloni A, et al. Amniocentesis and chorionic villus sampling in HIV-infected pregnant women: a multicentre case series. BJOG 2016.
  65. Simões M, Marques C, Gonçalves A, et al. Amniocentesis in HIV pregnant women: 16 years of experience. Infect Dis Obstet Gynecol 2013; 2013:914272.
  66. Constantatos SN, Boutall AH, Stewart CJ. Recommendations for amniocentesis in HIV-positive women. S Afr Med J 2014; 104:844.
  67. Ko TM, Tseng LH, Chang MH, et al. Amniocentesis in mothers who are hepatitis B virus carriers does not expose the infant to an increased risk of hepatitis B virus infection. Arch Gynecol Obstet 1994; 255:25.
  68. Alexander JM, Ramus R, Jackson G, et al. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect Dis Obstet Gynecol 1999; 7:283.
  69. Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001; 184:1514.
  70. Yi W, Pan CQ, Hao J, et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J Hepatol 2014; 60:523.
  71. Bui TH, Iselius L, Lindsten J. European collaborative study on prenatal diagnosis: mosaicism, pseudomosaicism and single abnormal cells in amniotic fluid cell cultures. Prenat Diagn 1984; 4 Spec No:145.
  72. Hsu LY, Kaffe S, Jenkins EC, et al. Proposed guidelines for diagnosis of chromosome mosaicism in amniocytes based on data derived from chromosome mosaicism and pseudomosaicism studies. Prenat Diagn 1992; 12:555.
  73. Eddleman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108:1067.
  74. Mazza V, Pati M, Bertucci E, et al. Age-specific risk of fetal loss post second trimester amniocentesis: analysis of 5043 cases. Prenat Diagn 2007; 27:180.
  75. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110:687.
  76. Halliday JL, Lumley J, Sheffield LJ, et al. Importance of complete follow-up of spontaneous fetal loss after amniocentesis and chorion villus sampling. Lancet 1992; 340:886.
  77. Welch RA, Salem-Elgharib S, Wiktor AE, et al. Operator experience and sample quality in genetic amniocentesis. Am J Obstet Gynecol 2006; 194:189.
  78. Hockstein S, Chen PX, Thangavelu M, Pergament E. Factors associated with maternal cell contamination in amniocentesis samples as evaluated by fluorescent in situ hybridization. Obstet Gynecol 1998; 92:551.
  79. Bakker M, Birnie E, Robles de Medina P, et al. Total pregnancy loss after chorionic villus sampling and amniocentesis - A cohort study. Ultrasound Obstet Gynecol 2016.
  80. Caughey AB, Hopkins LM, Norton ME. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 2006; 108:612.
  81. Towner D, Currier RJ, Lorey FW, et al. Miscarriage risk from amniocentesis performed for abnormal maternal serum screening. Am J Obstet Gynecol 2007; 196:608.e1.
  82. Harper LM, Cahill AG, Smith K, et al. Effect of maternal obesity on the risk of fetal loss after amniocentesis and chorionic villus sampling. Obstet Gynecol 2012; 119:745.
  83. Mackenzie WE, Holmes DS, Newton JR. Spontaneous abortion rate in ultrasonographically viable pregnancies. Obstet Gynecol 1988; 71:81.
  84. Risch HA, Weiss NS, Clarke EA, Miller AB. Risk factors for spontaneous abortion and its recurrence. Am J Epidemiol 1988; 128:420.
  85. Cohen-Overbeek TE, Hop WC, den Ouden M, et al. Spontaneous abortion rate and advanced maternal age: consequences for prenatal diagnosis. Lancet 1990; 336:27.
  86. Muller F, Thibaud D, Poloce F, et al. Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers. Prenat Diagn 2002; 22:1036.
  87. Akolekar R, Beta J, Picciarelli G, et al. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 45:16.
  88. Lindgren P, Cederholm M, Haglund B, Axelsson O. Invasive procedures for fetal karyotyping: no cause of subsequent gestational hypertension or pre-eclampsia. BJOG 2010; 117:1422.
  89. Mazza V, Pati M, Bertucci E, et al. Second trimester amniocentesis is not a risk factor for very low birth weight and extremely low birth weight. ISRN Obstet Gynecol 2011; 2011:313206.
  90. Cederholm M, Haglund B, Axelsson O. Maternal complications following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG 2003; 110:392.
  91. Hodor JG, Poggi SH, Spong CY, et al. Risk of third-trimester amniocentesis: a case-control study. Am J Perinatol 2006; 23:177.
  92. Yeast JD, Garite TJ, Dorchester W. The risks of amniocentesis in the management of premature rupture of the membranes. Am J Obstet Gynecol 1984; 149:505.
  93. Haeusler MC, Konstantiniuk P, Dorfer M, Weiss PA. Amniotic fluid insulin testing in gestational diabetes: safety and acceptance of amniocentesis. Am J Obstet Gynecol 1998; 179:917.
  94. Stark CM, Smith RS, Lagrandeur RM, et al. Need for urgent delivery after third-trimester amniocentesis. Obstet Gynecol 2000; 95:48.
  95. Gordon MC, Narula K, O'Shaughnessy R, Barth WH Jr. Complications of third-trimester amniocentesis using continuous ultrasound guidance. Obstet Gynecol 2002; 99:255.
  96. Gabbay-Benziv R, Yogev Y, Melamed N, et al. Pregnancy outcome after third trimester amniocentesis: a single center experience. J Matern Fetal Neonatal Med 2012; 25:666.
  97. Simonazzi G, Curti A, Farina A, et al. Amniocentesis and chorionic villus sampling in twin gestations: which is the best sampling technique? Am J Obstet Gynecol 2010; 202:365.e1.
  98. Weisz B, Rodeck CH. Invasive diagnostic procedures in twin pregnancies. Prenat Diagn 2005; 25:751.
  99. Rustico MA, Baietti MG, Coviello D, et al. Managing twins discordant for fetal anomaly. Prenat Diagn 2005; 25:766.
  100. Jeanty P, Shah D, Roussis P. Single-needle insertion in twin amniocentesis. J Ultrasound Med 1990; 9:511.
  101. van Vugt JM, Nieuwint A, van Geijn HP. Single-needle insertion: an alternative technique for early second-trimester genetic twin amniocentesis. Fetal Diagn Ther 1995; 10:178.
  102. Buscaglia M, Ghisoni L, Bellotti M, et al. Genetic amniocentesis in biamniotic twin pregnancies by a single transabdominal insertion of the needle. Prenat Diagn 1995; 15:17.
  103. Sebire NJ, Noble PL, Odibo A, et al. Single uterine entry for genetic amniocentesis in twin pregnancies. Ultrasound Obstet Gynecol 1996; 7:26.
  104. Vink J, Fuchs K, D'Alton ME. Amniocentesis in twin pregnancies: a systematic review of the literature. Prenat Diagn 2012; 32:409.
  105. Agarwal K, Alfirevic Z. Pregnancy loss after chorionic villus sampling and genetic amniocentesis in twin pregnancies: a systematic review. Ultrasound Obstet Gynecol 2012; 40:128.
  106. Antsaklis A, Souka AP, Daskalakis G, et al. Second-trimester amniocentesis vs. chorionic villus sampling for prenatal diagnosis in multiple gestations. Ultrasound Obstet Gynecol 2002; 20:476.
  107. Wapner RJ, Johnson A, Davis G, et al. Prenatal diagnosis in twin gestations: a comparison between second-trimester amniocentesis and first-trimester chorionic villus sampling. Obstet Gynecol 1993; 82:49.